Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Published Online: 2024-01-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Amer M Zeidan•Anna Jonášová•Annat Ikin•David Valcárcel•Faye Feller•Fei Huang•Laurie J Sherman•Libo Sun•Maria Díez-Campelo•Michael R Savona•Mikkael A Sekeres•Petra Bělohlávková•Pierre Fenaux•Qi Xia•Rami S Komrokji•Sheetal Shah•Shyamala Navada•Souria Dougherty•Thomas Illmer•Tymara Berry•Uwe Platzbecker•Valeria Santini•Yazan F Madanat•Ying Wan
